Fulgent Genetics Stock Performance
| FLGT Stock | USD 20.36 0.25 1.24% |
The firm shows a Beta (market volatility) of 1.47, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Fulgent Genetics will likely underperform. Fulgent Genetics has an expected return of -0.39%. Please make sure to confirm Fulgent Genetics maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Fulgent Genetics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Fulgent Genetics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in May 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 0.0996 | Five Day Return (4.28) | Year To Date Return (31.34) | Ten Year Return 119.06 | All Time Return 119.06 |
1 | Payment of 4683 shares by Jian Xie of Fulgent Genetics subject to Rule 16b-3 | 01/30/2024 |
2 | Payment of 6719 shares by Jian Xie of Fulgent Genetics subject to Rule 16b-3 | 02/06/2024 |
3 | Cord Blood Registry by CooperSurgical and Fulgent Genetics Launch Innovative Genetic Testing | 02/09/2024 |
4 | Disposition of 8667 shares by Ming Hsieh of Fulgent Genetics at 24.06 subject to Rule 16b-3 | 02/23/2024 |
5 | Acquisition by Jian Xie of 27 shares of Fulgent Genetics subject to Rule 16b-3 | 02/26/2024 |
6 | Fulgent Genetics Inc Faces GAAP Loss Despite Core Revenue Growth in 2023 | 02/28/2024 |
7 | Fulgent Genetics Releases FY 2024 Earnings Guidance | 02/29/2024 |
8 | Are Investors Undervaluing Fulgent Genetics, Inc. By 32 | 03/01/2024 |
9 | Disposition of 1075 shares by Jian Xie of Fulgent Genetics at 23.24 subject to Rule 16b-3 | 03/05/2024 |
10 | Disposition of 1000000 shares by Ming Hsieh of Fulgent Genetics subject to Rule 16b-3 | 03/08/2024 |
11 | Trading Advice - Stock Traders Daily | 03/22/2024 |
12 | Disposition of 865 shares by Paul Kim of Fulgent Genetics at 29.33 subject to Rule 16b-3 | 03/27/2024 |
13 | Reproductive Genetics Market Analysis Report 2024-2032, Featuring Bangkok Genomics Innovation, Centogene, Fulgent Genetics, Igenomix, Invitae, PerkinElmer and T... | 03/28/2024 |
14 | SG Americas Securities LLC Lowers Holdings in Fulgent Genetics, Inc. - Defense World | 04/08/2024 |
| Begin Period Cash Flow | 79.5 M |
Fulgent |
Fulgent Genetics Relative Risk vs. Return Landscape
If you would invest 2,645 in Fulgent Genetics on January 20, 2024 and sell it today you would lose (609.00) from holding Fulgent Genetics or give up 23.02% of portfolio value over 90 days. Fulgent Genetics is currently does not generate positive expected returns and assumes 2.3367% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Fulgent, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fulgent Genetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fulgent Genetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fulgent Genetics, and traders can use it to determine the average amount a Fulgent Genetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1658
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FLGT |
Estimated Market Risk
| 2.34 actual daily | 20 80% of assets are more volatile |
Expected Return
| -0.39 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Fulgent Genetics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fulgent Genetics by adding Fulgent Genetics to a well-diversified portfolio.
Fulgent Genetics Fundamentals Growth
Fulgent Stock prices reflect investors' perceptions of the future prospects and financial health of Fulgent Genetics, and Fulgent Genetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fulgent Stock performance.
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0347 | ||||
| Profit Margin | (0.58) % | ||||
| Operating Margin | (0.47) % | ||||
| Current Valuation | 185 M | ||||
| Shares Outstanding | 29.9 M | ||||
| Price To Earning | 3.95 X | ||||
| Price To Book | 0.55 X | ||||
| Price To Sales | 2.15 X | ||||
| Revenue | 289.21 M | ||||
| Gross Profit | 366.9 M | ||||
| EBITDA | (43.54 M) | ||||
| Net Income | (167.82 M) | ||||
| Cash And Equivalents | 515.4 M | ||||
| Cash Per Share | 17.03 X | ||||
| Total Debt | 14.91 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 5.29 X | ||||
| Book Value Per Share | 38.31 X | ||||
| Cash Flow From Operations | 27 M | ||||
| Earnings Per Share | (5.63) X | ||||
| Market Capitalization | 601.3 M | ||||
| Total Asset | 1.27 B | ||||
| Retained Earnings | 633.17 M | ||||
| Working Capital | 434.83 M | ||||
| Current Asset | 2.93 M | ||||
| Current Liabilities | 686 K | ||||
About Fulgent Genetics Performance
To evaluate Fulgent Genetics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Fulgent Genetics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Fulgent Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Fulgent Genetics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Fulgent's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 11.04 | 10.49 | |
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.06) | (0.07) | |
| Return On Assets | (0.13) | (0.14) | |
| Return On Equity | (0.15) | (0.16) |
Things to note about Fulgent Genetics performance evaluation
Checking the ongoing alerts about Fulgent Genetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fulgent Genetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fulgent Genetics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 289.21 M. Net Loss for the year was (167.82 M) with profit before overhead, payroll, taxes, and interest of 366.9 M. | |
| About 33.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: SG Americas Securities LLC Lowers Holdings in Fulgent Genetics, Inc. - Defense World |
- Analyzing Fulgent Genetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fulgent Genetics' stock is overvalued or undervalued compared to its peers.
- Examining Fulgent Genetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fulgent Genetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fulgent Genetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fulgent Genetics' stock. These opinions can provide insight into Fulgent Genetics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.Note that the Fulgent Genetics information on this page should be used as a complementary analysis to other Fulgent Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Fulgent Stock analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (5.63) | Revenue Per Share 9.71 | Quarterly Revenue Growth 0.041 | Return On Assets (0.03) |
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.